GPhA Issues Statement on Pfizer's Press Release
Posted on: Thursday, 9 February 2006, 18:00 CST
ARLINGTON, Va., Feb. 9 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) today issued the following statement in response to Pfizer's February 8 press release. GPhA has not reviewed the citizen petition referred to in Pfizer's release and, as a general matter, does not comment on patent litigation matters. However, because the press release contained an unwarranted business practice, GPhA is compelled to respond.
"Our nation would be better served if Pfizer focused its resources on research and innovation, rather than unwarranted attacks on FDA's generic approval process and attempts to undermine America's confidence in generic medicines," said Kathleen Jaeger, GPhA President and CEO.
"It's disappointing to see a leader in the pharmaceutical industry such as Pfizer try to make this litigation issue about consumer confidence in affordable generics.
"They know, just as we know, that FDA-approved generics provide the same medicine and the same results as brands," said Jaeger. "For more than 20 years, America's generic pharmaceutical industry has been improving lives for less."
Generics represent 53% of the total prescriptions dispensed in the United States, but less than 12% of all dollars spent on prescription drugs. Pfizer's press release calls into question certain attributes of generic medicines, yet it has been FDA's long-standing policy that products containing the same active ingredient with different waters of hydration (i.e., molecules of water, such as monohydrate, dihydrate) are considered to be the same active ingredient and are deemed to be pharmaceutically equivalent (substitutable). See "FDA's Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly referred to as the Orange Book) at XV (2005).
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. For more information about the industry, visit http://www.gphaonline.org/.
First Call Analyst: FCMN Contact:
GPhA
CONTACT: Andrea Hofelich of GPhA, +1-703-647-2495
Web site: http://www.gphaonline.org/
Source: PRNewswire
Related Articles
- Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use
- Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
- Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
- Network Intercept Releases Scan-on-the-Go(TM) Active State
- KV Pharmaceutical Gets FDA Approval for Generic Contin
- FDA OKs Mylan's Generic Norvasc
- Research and Markets: The Evolving Strategies of Generics Company Teva and the Growing Acceptance of Generic Drugs in Japan, Read More Inside 'State of the Pharmaceutical Industry, 2007'
- Teva Receives FDA Approval for Generic Zoloft(R) Tablets
- Administration's Inadequate Funding for FDA's Office of Generic Drugs Is 'Penny-Wise and Pound-Foolish,' Says GPhA
- Pfizer Wins Right to Block Lipitor Generic
 |
 |
User Comments (0)
RSS Feeds